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Wednesday, February 11, 2015 583amonitor and regulate intracellular calcium and are ideal pharmacological
targets for immunosuppression, fibroproliferative disorders, hypertension and
various neurological diseases. However, the development of drugs specifically
for these medically relevant channels faces serious challenges because there is
no available crystal structure that could be used for structure-assisted drug
design. We used the Kv1.2-Kv2.1 channel structure (pdb id: 2R9R) as a tem-
plate to generate a homology model of the KCa3.1 channel transmembrane
region using the Rosetta modeling method. Docking of small molecules that
are known to block KCa3.1 channel currents using Rosetta generated structural
models of channel - drug complexes that can be validated using experimental
approaches. Here we report the validation of the binding sites for the dihydro-
pyridine nifedipine predicted by Rosetta’s lowest energy stimulation of the
KCa3.1 channel complex. We used a combination of site-directed mutagenesis
and electrophysiological patch-clamp recording to test the identified amino
acid residues located between the pore lining S5 and S6 segment. Blocking
of the KCa3.1 channel by nifedipine was reduced by altering the side chains
at positions L209, T212 and V278 to either alanine or valine, with T212 the
most affected residue. Bulkier side-chain change to phenylalanine confirmed
T212 as the main interacting site for nifedipine without compromising the
channel’s affinity for TRAM-34. Thus, by correctly identified the interaction
of the dihydropyridine nifedipine with the KCa3.1 channel complex, Rosetta
models can be used to understand the molecular mechanism of action of
KCa channel blockers and gating modulators and assist with drug design
efforts.
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GBR-12909 (vanoxerine) is a potent highly selective dopamine transporter
antagonist. It was initially developed for treatment of Parkinson’s disease
and while safe in man, lacked efficacy. Although a potent hERG blocker,
the drug exhibits multiple ion channel effects including frequency-
dependence. The drug effectively terminated induced, sustained atrial fibril-
lation (AF) and atrial flutter in a canine model of sterile pericarditis.
Subsequently the drug terminated AF in a Phase 2B ascending dose trial. Pre-
vious in vitro measurements used protocols that did not address the issue of the
late Nav1.5 current which is important in understanding safety of a potent
hERG blocker.
Peak and late sodium currents were measured in HEK-293 cells stably ex-
pressing the human Nav1.5 channel. Peak currents were measured using a
step-ramp protocol consisting of a 40 ms step to 15 mV (where the peak
current was measured), a 180 ms step to þ30 mV and a 200 ms ramp to
the holding potential of 80 mV (1 Hz stimulating frequency). The effect
of the drug was parameterized with a single binding isotherm having an
IC50 of 29 5 3 nM (95% CI: 22-37) and a Hill coefficient of 0.91 5 0.10
(95% CI: 0.68-1.18) (seven cells, three concentrations). We also evaluated
the effect of GBR-19209 on currents increased using the sea-anemone toxin
ATX-II as a surrogate of the late sodium current. The calculated IC50 and
Hill coefficients from five cells and five concentrations were 93 5 9 nM
(95% CI: 7-117) and 1.57 5 0.24 (95% CI: 1.05-2.67), respectively. Thus,
GBR-12909 block is at least sixty times more potent than ranolazine’s
(IC50 ¼ 6 mM).The combination of potent peak and late sodium block may
explain the antiarrhythmic and safe profile of the drug.
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Understanding how small molecules potentiate CFTR gating is critical for
developing novel therapy for cystic fibrosis. Our previous studies have sug-
gested that VX-770 (ivacaftor), a CFTR potentiator now used in clinics,
increases the Po of CFTR by shifting the gating conformational changes in
CFTR’s transmembrane domains (TMDs) to favor the open channel configura-
tion. Lately, another CFTR potentiator NPPB was reported to enhance CFTR
activity through a modus operandi that exploits the ATP hydrolysis-driven,
non-equilibrium gating mechanism unique to CFTR. It is however puzzling
that NPPB can also increase the activity of non-hydrolytic G551D-CFTR,
the third most common pathogenic mutation. We therefore set forth to unravel
the mechanism of NPPB using VX-770 as a reference. Once the blocking effect
of NPPB was corrected, we found that NPPB and VX-770, when applied alone,
increased the Po of G551D-CFTR by 6.95 0.8 (n ¼ 12) and 9.35 1.4 (n ¼21) folds respectively. Once these two reagents were applied together, how-
ever, the Po was increased by 28.985 7.6 fold (n¼ 10), less than the expected
magnitude (~ 60-fold) if NPPB and VX-770 work independently. Hence, NPPB
only increases the Po of G551D-CFTR by 3.75 0.4 fold (n ¼ 9) in the pres-
ence of VX-770. Similarly, a much reduced enhancement (4.85 1.8 fold, n ¼
5) of the Po by VX-770 in the presence of NPPB was seen. Interestingly, we
also observed that VX-770 effectively potentiates a CFTR mutant with its sec-
ond nucleotide-binding domain completely removed (i.e., dNBD2), whereas
NPPB has virtually no effect (n ¼ 12). These results can be explained by a
gating model featuring an energetic coupling between opening/closing of the
gate in TMDs where VX-770 binds and dimerization/dissociation of NBDs
where NPPB acts on.
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‘‘Use-’’ or ‘‘state-’’ dependent block of voltage-gated sodium channels is
characteristic of therapeutic agents used to moderate electrical activity in path-
ologically hyperactive tissues and combat certain forms of epilepsy, cardiac
arrhythmia, myotonia, and pain. Externally acting Na channel pore blockers
are not commonly used as therapeutic drugs, but intraperitoneal m-conotoxin
(mCTX) KIIIA can act as an effective analgesic against inflammatory pain in
mice, at concentrations that do not cause obvious systemic side effects (Zhang
et al 2007 J Biol Chem 42:30699). This action appears to result from highly
specific targeting to neuronal Na channels, without essential reliance on the
use-dependent potency that contributes to the efficacy of clinical local anes-
thetics. mCTXs, although highly selective among closely related eukaryotic
Na channels, have recently been found to block bacterial Nav channels with
high affinity (Chen & Chung 2012 Biophys J 102:483; Finol-Urdaneta et al
2013 Biophys J 104:136a). In addition, the block was potentiated at more de-
polarized holding potentials. Here, we explore the dependence of mCTX PIIIA
block of NaChBac and NavSp1 on varying patterns of conditioning depolari-
zation. Briefly, in the low picomolar range, PIIIA application was associated
with faster inactivation decay during a test depolarization, and block of the
peak current. The speeding of inactivation precedes the block of current
following PIIIA application, and this kinetic effect was obvious at more nega-
tive holding potentials than was the decrease in peak current. In NaChBac, both
activation and inactivation were shifted in the hyperpolarizing direction by
~25-30 mV in the presence of 5pM PIIIA. The data suggest that PIIIA binding
is conformation dependent, with high affinity for non-conducting, depolariza-
tion-induced states. At present, the relative importance of ‘‘pre-activated’’
and ‘‘in-activated’’ states in potentiating inhibition by PIIIA is unclear.
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Sodium absorption in epithelial cells is rate-limited by the epithelial sodium
channel (ENaC) activity in lungs, kidney and the distal colon. Pathophysiolog-
ical conditions, such as cystic fibrosis and Liddle syndrome, result from water-
electrolyte imbalance partly due to malfunction of ENaC’s molecular regu-
lation. The molecular mechanism(s) of pathologically implicated mutations
in ENaC subunits are largely unknown due to absence of structural models
for ENaC’s oligomers. Here, we propose a dynamics-driven mechanism of
the gain of function mutation aW493R implicated in atypical cystic fibrosis.
We utilize a combination of discrete molecular dynamics simulations (DMD)
of the extracellular region of ENaC’s heterotrimer abg and functional data
from whole-cell electrophysiology experiments. Structure-function studies
suggest that tetramers and trimers are the major characterized functional olig-
omeric states of ENaC. Using the crystal structure of the acid sensing ion chan-
nel, ENaC’s structural homolog in the ENaC/degenerin mechanosensitive
ion channel family, we have constructed homology models of ENaC subunits
alpha, beta and gamma, in addition to the heterotrimers abg, agb and the
heterotetramer abag. Electrophysiology data show constitutive activity of
aW493Rbg in oocytes indicated by higher open probability and elevated basal
activity compared to WT. Our DMD simulation provides an allosteric frame-
work, which agrees with experimental data. W493R rewires the electrostati-
cally mediated inter-residue interaction network in close proximity to W493,
resulting in widening of the pore geometry in the outer mouth of the pore in
